Delandistrogene moxeparvovec received FDA approval after a negative trial, which highlights the many complexities and challenges of drug development in this setting.

中文翻译：

---

杜氏肌营养不良症阴性基因治疗试验的经验教训


Delandistrogene moxeparvovec 在一次否定试验后获得了 FDA 的批准，这凸显了在这种情况下药物开发的许多复杂性和挑战。